NanoViricides Highlights Broad-Spectrum Antiviral Candidate Following Andes Hantavirus Incident

NanoViricides, Inc. (NYSE American: NNVC) highlighted the potential need for broad-spectrum antiviral treatments following the recent Andes hantavirus incident aboard a cruise ship, pointing to its clinical-stage antiviral candidate NV-387 as a potential therapeutic platform for emerging viral threats. The company said NV-387 has completed a Phase I safety and tolerability trial in healthy volunteers and has demonstrated effectiveness in animal models involving multiple viral lung infections, including coronaviruses, RSV, influenza, monkeypox and measles, as it advances development of a platform designed to target a broad range of pathogenic viral infections.

The announcement comes after a reported case of Andes hantavirus on a cruise ship, underscoring the unpredictable nature of viral outbreaks and the need for treatments that can address a variety of pathogens. Hantaviruses, which are primarily transmitted through rodent droppings, can cause severe respiratory illness and have a high mortality rate. The Andes strain is particularly concerning because it can also be transmitted from person to person. NanoViricides' NV-387 is a broad-spectrum antiviral drug that has shown efficacy in animal models against several viruses, including those that cause respiratory infections. The drug candidate is designed to mimic the host cell surface, thereby interfering with the virus's ability to attach and enter cells.

NV-387 has successfully completed a Phase I human clinical trial in healthy volunteers with no reported adverse events, according to the company. NanoViricides is currently focused on advancing NV-387 into Phase II human clinical trials. The company's drug development pipeline also includes NV-HHV-1 for herpesvirus infections. The potential for NV-387 to treat a wide range of viral infections could make it a valuable asset in the fight against future pandemics and emerging infectious diseases.

For more information, visit the company's newsroom at https://ibn.fm/NNVC and the full press release at https://ibn.fm/OYkof.